Trial Profile

APEX-Part II study of bezuclastinib in patients with mastocytosis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bezuclastinib (Primary)
Indications Mastocytosis
Focus Adverse reactions; Therapeutic Use
Acronyms APEX Part-2

Most Recent Events

20 Mar 2023 According to Cogent media release, APEX part II study planned for initiation based on clinical data from approximately 25-30 patients in APEX Part 1. Updates are expected in mid-year 2023.
20 Mar 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com